Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
41. lappuse
... Packaging . If the product contains 30 milligrams or more of iron per dos- age unit , it shall be packaged in unit- dose packaging . “ Unit - dose packaging " means a method of packaging a prod- uct into a nonreusable container de ...
... Packaging . If the product contains 30 milligrams or more of iron per dos- age unit , it shall be packaged in unit- dose packaging . “ Unit - dose packaging " means a method of packaging a prod- uct into a nonreusable container de ...
230. lappuse
... packaged in a pressurized con- tainer with suitable inert gases : Pro- vided , That is meets the tests and methods of assay in §448.513e ( b ) of this chapter . ( 8 ) Bacitracin zinc - polymyxin B sul- fate topical powder containing ...
... packaged in a pressurized con- tainer with suitable inert gases : Pro- vided , That is meets the tests and methods of assay in §448.513e ( b ) of this chapter . ( 8 ) Bacitracin zinc - polymyxin B sul- fate topical powder containing ...
297. lappuse
... packaged in a self - pres- surized container in which the propel- lant consists in whole or in part of a halocarbon or hydrocarbon shall bear the following warning : Warning - Use only as directed . Inten- tional misuse by deliberately ...
... packaged in a self - pres- surized container in which the propel- lant consists in whole or in part of a halocarbon or hydrocarbon shall bear the following warning : Warning - Use only as directed . Inten- tional misuse by deliberately ...
306. lappuse
... packaged as to maintain its representative char- acter , and in the case of any solution or suspension , shall be collected and packaged under aseptic conditions . Each package shall be clearly identi- fied as to its contents and shall ...
... packaged as to maintain its representative char- acter , and in the case of any solution or suspension , shall be collected and packaged under aseptic conditions . Each package shall be clearly identi- fied as to its contents and shall ...
332. lappuse
... packaging the batch that the quan- tities packaged during the intervals are approximately equal . In no case , however , shall more than 5,000 imme- diate containers have been packaged during each such interval of sampling , except for ...
... packaging the batch that the quan- tities packaged during the intervals are approximately equal . In no case , however , shall more than 5,000 imme- diate containers have been packaged during each such interval of sampling , except for ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning